Citation

Goldberg JF, Citrome L. SENDROM 2006; 18(2): 32-38.

Copyright

(Copyright © 2006)

DOI

unavailable

PMID

unavailable

Abstract

Effective treatments of bipolar disorder now extend to panoply of choices that include various anticonvulsants and antipsychotics. Although lithium still has an important role, particularly in "classic" mania and suicide prevention, the other PDA-approved agents are better tolerated and more efficacious for mixed states and rapid cycling. It is not uncommon to use combination therapy for this challenging disorder. The FDA has approved olanzapine, and fluoxetine for acute bipolar depression. Maintenance treatments that have received FDA approval include clanzapine and lamotrigine. Off-label use of adjunctive medications may be required to targed residual symptoms.

Language: tr

Keywords

human; suicide; bipolar disorder; lithium; clozapine; article; anticonvulsive agent; neuroleptic agent; fluoxetine; quetiapine; food and drug administration; carbamazepine; extrapyramidal symptom; olanzapine; risperidone; tardive dyskinesia; valproate semisodium; agranulocytosis; hyperprolactinemia; hypotension; mania; rash; chlorpromazine; lamotrigine; maintenance therapy; metabolic disorder; ziprasidone; QT prolongation; oxcarbazepine; aripiprazole; thrombosis; uremia; rapid cycling bipolar disorder; mixed mania and depression; off label drug use